103 related articles for article (PubMed ID: 7533342)
1. Location of WESb on decay-accelerating factor.
Telen MJ; Rao N; Lublin DM
Transfusion; 1995 Mar; 35(3):278. PubMed ID: 7533342
[No Abstract] [Full Text] [Related]
2. Blood group antigens on complement receptor/regulatory proteins.
Telen MJ
Transfus Med Rev; 1995 Jan; 9(1):20-8. PubMed ID: 7536497
[No Abstract] [Full Text] [Related]
3. Separation of self from non-self in the complement system: a role for membrane cofactor protein and decay accelerating factor.
Atkinson JP; Oglesby TJ; White D; Adams EA; Liszewski MK
Clin Exp Immunol; 1991 Oct; 86 Suppl 1(Suppl 1):27-30. PubMed ID: 1718640
[No Abstract] [Full Text] [Related]
4. Use of the MAIEA technique to confirm the relationship between the Cromer antigens and decay-accelerating factor and to assign provisionally antigens to the short-consensus repeats.
Petty AC; Daniels GL; Anstee DJ; Tippett P
Vox Sang; 1993; 65(4):309-15. PubMed ID: 7508660
[TBL] [Abstract][Full Text] [Related]
5. Structure and function of decay accelerating factor CD55.
Nicholson-Weller A; Wang CE
J Lab Clin Med; 1994 Apr; 123(4):485-91. PubMed ID: 7511675
[TBL] [Abstract][Full Text] [Related]
6. Short consensus repeat-3 domain of recombinant decay-accelerating factor is recognized by Escherichia coli recombinant Dr adhesin in a model of a cell-cell interaction.
Nowicki B; Hart A; Coyne KE; Lublin DM; Nowicki S
J Exp Med; 1993 Dec; 178(6):2115-21. PubMed ID: 7504058
[TBL] [Abstract][Full Text] [Related]
7. Interactions of CD55 with non-complement ligands.
Lea S
Biochem Soc Trans; 2002 Nov; 30(Pt 6):1014-9. PubMed ID: 12440964
[TBL] [Abstract][Full Text] [Related]
8. Expression of a hybrid complement regulatory protein, membrane cofactor protein decay accelerating factor on Chinese hamster ovary. Comparison of its regulatory effect with those of decay accelerating factor and membrane cofactor protein.
Iwata K; Seya T; Ariga H; Nagasawa S
J Immunol; 1994 Apr; 152(7):3436-44. PubMed ID: 7511647
[TBL] [Abstract][Full Text] [Related]
9. Characterization of DAF-2, a high molecular weight form of decay-accelerating factor (DAF; CD55), as a covalently cross-linked dimer of DAF-1.
Nickells MW; Alvarez JI; Lublin DM; Atkinson JP
J Immunol; 1994 Jan; 152(2):676-85. PubMed ID: 7506731
[TBL] [Abstract][Full Text] [Related]
10. More about use of the term Drb.
Lewis M; McAlpine PJ
Transfusion; 1993 Feb; 33(2):182. PubMed ID: 7679228
[No Abstract] [Full Text] [Related]
11. Aberrant expression of complement regulatory proteins, membrane cofactor protein and decay accelerating factor, in the involved epidermis of patients with vitiligo.
van den Wijngaard RM; Asghar SS; Pijnenborg AC; Tigges AJ; Westerhof W; Das PK
Br J Dermatol; 2002 Jan; 146(1):80-7. PubMed ID: 11841370
[TBL] [Abstract][Full Text] [Related]
12. Structural properties of the glycoplasmanylinositol anchor phospholipid of the complement membrane attack complex inhibitor CD59.
Ratnoff WD; Knez JJ; Prince GM; Okada H; Lachmann PJ; Medof ME
Clin Exp Immunol; 1992 Mar; 87(3):415-21. PubMed ID: 1371955
[TBL] [Abstract][Full Text] [Related]
13. Hemagglutination inhibition of Cromer blood group antibodies with soluble recombinant decay-accelerating factor.
Daniels GL; Green CA; Powell RM; Ward T
Transfusion; 1998 Apr; 38(4):332-6. PubMed ID: 9595014
[TBL] [Abstract][Full Text] [Related]
14. Decay-accelerating factor (DAF, CD55) in normal colorectal mucosa, adenomas and carcinomas.
Koretz K; Brüderlein S; Henne C; Möller P
Br J Cancer; 1992 Nov; 66(5):810-4. PubMed ID: 1384641
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the active sites in decay-accelerating factor.
Kuttner-Kondo LA; Mitchell L; Hourcade DE; Medof ME
J Immunol; 2001 Aug; 167(4):2164-71. PubMed ID: 11490001
[TBL] [Abstract][Full Text] [Related]
16. Decay-accelerating factor (CD55) is expressed by neurons in response to chronic but not acute autoimmune central nervous system inflammation associated with complement activation.
van Beek J; van Meurs M; 't Hart BA; Brok HP; Neal JW; Chatagner A; Harris CL; Omidvar N; Morgan BP; Laman JD; Gasque P
J Immunol; 2005 Feb; 174(4):2353-65. PubMed ID: 15699172
[TBL] [Abstract][Full Text] [Related]
17. Solubilization of glycosyl-phosphatidylinositol-anchored proteins in quiescent and stimulated neutrophils.
Cain TJ; Liu Y; Takizawa T; Robinson JM
Biochim Biophys Acta; 1995 Apr; 1235(1):69-78. PubMed ID: 7536473
[TBL] [Abstract][Full Text] [Related]
18. Expression of complement regulatory proteins [membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59)] in endometrial stressed cells.
Iborra A; Mayorga M; Llobet N; Martínez P
Cell Immunol; 2003 May; 223(1):46-51. PubMed ID: 12914757
[TBL] [Abstract][Full Text] [Related]
19. Flow cytometric analysis of decay-accelerating factor (CD55) on neutrophils from aplastic anaemia patients.
Forés R; Alcocer M; Diez-Martin JL; Fernandez MN
Br J Haematol; 1995 Jul; 90(3):728-30. PubMed ID: 7544152
[TBL] [Abstract][Full Text] [Related]
20. The expression of the complement regulators CD46, CD55, and CD59 by human sperm does not protect them from antisperm antibody- and complement-mediated immune injury.
D'Cruz OJ; Haas GG
Fertil Steril; 1993 Apr; 59(4):876-84. PubMed ID: 7681414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
